CRDF

CRDF R&D to Revenue

5957.67%Fiscal year

Period ending:

CRDF FY R&D/Revenue%
CRDF FY R&D/Revenue7865.24%-842.70%
2005-01-312025-12-31

Source: Financial Modeling Prep (FMP). Annual fiscal periods. Dates are period ends; a fiscal year may differ from a calendar year.

CRDF r&d to revenue history

R&D spending as percentage of revenue. The available annual fiscal periods series contains 19 observations from Jan 31, 2005 to Dec 31, 2025.

Cardiff Oncology Inc R&D to Revenue — Annual fiscal periods
Period endingR&D to Revenue
5,957.6728%
5,395.6076%
6,732.9918%
7,022.5389%
4,840.1114%
3,069.6721%
4,562.8683%
2,159.7884%
1,560.9901%
3,938.8451%
3,384.6645%
2,380.3571%
1,522.7193%
426.6667%
353.3951%
1,389.3543%
0%
0%
0%

Compare r&d to revenue

All CRDF financial metrics · CRDF stock overview · How to interpret financial metrics

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.